SARC044 June 19, 2024 Phase II Trial of bezuclastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy. TYPE OF SARCOMA: Gastrointestinal stromal tumor (GIST)DRUG: Bezuclastinib in combination with sunitinib ACCRUAL STATUS: Now recruiting for patients OVERALL PRINCIPLE INVESTIGATOR: Candace Haddox, MD Dana Farber Cancer Institute CLINICALTRIALS.GOV IDENTIFIER: NCT06208748 FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICAL TRIALS